Literature DB >> 33553201

Complement, a Therapeutic Target in Diabetic Kidney Disease.

Kelly Budge1, Sergio Dellepiane1, Samuel Mon-Wei Yu1, Paolo Cravedi1.   

Abstract

Currently available treatments of diabetic kidney disease (DKD) remain limited despite improved understanding of DKD pathophysiology. The complement system is a central part of innate immunity, but its dysregulated activation is detrimental and results in systemic diseases with overt inflammation. Growing evidence suggests complement activation in DKD. With existent drugs and clinical success of treating other kidney diseases, complement inhibition has emerged as a potential novel therapy to halt the progression of DKD. This article will review DKD, the complement system's role in diabetic and non-diabetic disease, and the potential benefits of complement targeting therapies especially for DKD patients.
Copyright © 2021 Budge, Dellepiane, Yu and Cravedi.

Entities:  

Keywords:  C3a; C5a; MAC; complement; diabetes; diabetic kidney disease; glomerulosclerosis

Year:  2021        PMID: 33553201      PMCID: PMC7858668          DOI: 10.3389/fmed.2020.599236

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  80 in total

1.  C5aR1 regulates T follicular helper differentiation and chronic graft-versus-host disease bronchiolitis obliterans.

Authors:  Divya A Verghese; Nicholas Chun; Katelyn Paz; Miguel Fribourg; Trent M Woodruff; Ryan Flynn; Yuan Hu; Huabao Xiong; Weijia Zhang; Zhengzi Yi; Jing Du; Bruce R Blazar; Peter S Heeger
Journal:  JCI Insight       Date:  2018-12-20

2.  Does non-enzymatic glycosylation affect complement function in diabetes?

Authors:  P W Peake; J A Charlesworth; V Timmermans; L Gavrilovic; B Pussell
Journal:  Diabetes Res       Date:  1989-07

3.  C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/β-catenin signaling pathway in diabetic kidney disease.

Authors:  Ling Li; Lijia Chen; Jing Zang; Xi Tang; Yan Liu; Jie Zhang; Lin Bai; Qinghua Yin; Yanrong Lu; Jingqiu Cheng; Ping Fu; Fang Liu
Journal:  Metabolism       Date:  2015-01-29       Impact factor: 8.694

4.  Mannose-binding lectin and mortality in type 2 diabetes.

Authors:  Troels Krarup Hansen; Mari-Anne Gall; Lise Tarnow; Steffen Thiel; Coen D Stehouwer; Casper G Schalkwijk; Hans-Henrik Parving; Allan Flyvbjerg
Journal:  Arch Intern Med       Date:  2006-10-09

5.  Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.

Authors:  Carmen Lefaucheur; Denis Viglietti; Luis G Hidalgo; Lloyd E Ratner; Serena M Bagnasco; Ibrahim Batal; Olivier Aubert; Babak J Orandi; Federico Oppenheimer; Oriol Bestard; Paolo Rigotti; Anna V Reisaeter; Nassim Kamar; Yvon Lebranchu; Jean-Paul Duong Van Huyen; Patrick Bruneval; Denis Glotz; Christophe Legendre; Jean-Philippe Empana; Xavier Jouven; Dorry L Segev; Robert A Montgomery; Adriana Zeevi; Philip F Halloran; Alexandre Loupy
Journal:  J Am Soc Nephrol       Date:  2017-10-17       Impact factor: 10.121

6.  Complement activation products in the urine from proteinuric patients.

Authors:  Yoshiki Morita; Hiroshi Ikeguchi; Jiro Nakamura; Nigishi Hotta; Yukio Yuzawa; Seiichi Matsuo
Journal:  J Am Soc Nephrol       Date:  2000-04       Impact factor: 10.121

7.  Immune cell-derived C3a and C5a costimulate human T cell alloimmunity.

Authors:  P Cravedi; J Leventhal; P Lakhani; S C Ward; M J Donovan; P S Heeger
Journal:  Am J Transplant       Date:  2013-09-06       Impact factor: 8.086

Review 8.  A more tubulocentric view of diabetic kidney disease.

Authors:  Letizia Zeni; Anthony G W Norden; Giovanni Cancarini; Robert J Unwin
Journal:  J Nephrol       Date:  2017-08-24       Impact factor: 3.902

9.  Pathological significance of urinary complement activation in diabetic nephropathy: A full view from the development of the disease.

Authors:  Jing-Min Zheng; Zuan-Hong Jiang; De-Jun Chen; Sa-Sa Wang; Wen-Jin Zhao; Li-Juan Li
Journal:  J Diabetes Investig       Date:  2018-10-13       Impact factor: 4.232

10.  Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial.

Authors:  Peter A Merkel; David R Jayne; Chao Wang; Jan Hillson; Pirow Bekker
Journal:  JMIR Res Protoc       Date:  2020-04-07
View more
  6 in total

1.  Complement Deposition Predicts Worsening Kidney Function and Underlines the Clinical Significance of the 2010 Renal Pathology Society Classification of Diabetic Nephropathy.

Authors:  Shimin Jiang; Dingxin Di; Yuanyuan Jiao; Guming Zou; Hongmei Gao; Wenge Li
Journal:  Front Immunol       Date:  2022-05-27       Impact factor: 8.786

Review 2.  The Glomerulus According to the Mesangium.

Authors:  Kerstin Ebefors; Lovisa Bergwall; Jenny Nyström
Journal:  Front Med (Lausanne)       Date:  2022-01-26

3.  Activation of complement C1q and C3 in glomeruli might accelerate the progression of diabetic nephropathy: Evidence from transcriptomic data and renal histopathology.

Authors:  Yuanyuan Jiao; Shimin Jiang; Ying Wang; Tianyu Yu; Guming Zou; Li Zhuo; Wenge Li
Journal:  J Diabetes Investig       Date:  2022-01-10       Impact factor: 3.681

Review 4.  Molecular Mechanisms of Diabetic Kidney Disease.

Authors:  Jorge Rico-Fontalvo; Gustavo Aroca; Jose Cabrales; Rodrigo Daza-Arnedo; Tomas Yánez-Rodríguez; María Cristina Martínez-Ávila; Isabella Uparella-Gulfo; María Raad-Sarabia
Journal:  Int J Mol Sci       Date:  2022-08-04       Impact factor: 6.208

5.  Exploring the pathogenesis of diabetic kidney disease by microarray data analysis.

Authors:  Haiyan Cao; Xiaosheng Rao; Junya Jia; Tiekun Yan; Dong Li
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

6.  C4d Deposition after Allogeneic Renal Transplantation in Rats Is Involved in Initial Apoptotic Cell Clearance.

Authors:  Stefan Reuter; Dominik Kentrup; Alexander Grabner; Gabriele Köhler; Konrad Buscher; Bayram Edemir
Journal:  Cells       Date:  2021-12-10       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.